Atropine use in myopia control

Șcerbatiuc, Cristina; Bendelic, Eugeniu; Paduca, Ala

dc.contributor.author	Șcerbatiuc, Cristina
dc.contributor.author	Bendelic, Eugeniu
dc.contributor.author	Paduca, Ala
dc.date.accessioned	2023-04-12T07:41:27Z
dc.date.available	2023-04-12T07:41:27Z
dc.date.issued	2021
dc.identifier.citation	ȘCERBATIUC, Cristina, BENDELIC, Eugeniu, PADUCA, Ala. Atropine use in myopia control. In: 19th Black Sea Ophthalmological Society Congress, September 24-26, 2021, Chisinau, Republic of Moldova: abstract book, p. 75.	en_US
dc.identifier.uri	https://aom.md/wp-content/uploads/2021/10/ABSTRACT-BOOK_web.pdf
dc.identifier.uri	https://repository.usmf.md/handle/20.500.12710/24115
dc.description.abstract	Atropine is currently the most effective therapy for myopia control. Recent clinical trials demonstrated low-dose atropine eye drops such as 0.01% resulted in retardation of myopia progression, with less side effects compared to higher concentration preparation. For children aged 6-10 years with myopia of at least 1D and myopia progression of at least 0.50D per year, the WHO recommends atropine as a potential first line treatment for myopia. Proposed strategies include a combination of low-dose atropine with increase outdoor time. We made pilot study and 1-year results suggest that atropine 0.01% eyedrops can slow myopia progression and axial elongation of the eye.	en_US
dc.language.iso	en	en_US
dc.publisher	Black Sea Ophthalmological Society, Ophthalmological Association from Moldova, Nicolae Testemitanu State University of Medicine and Pharmacy of the Republic of Moldova	en_US
dc.relation.ispartof	19th Black Sea Ophthalmological Society Congress, September 24-26, 2021 Chisinau, Republic of Moldova	en_US
dc.title	Atropine use in myopia control	en_US
dc.type	Other	en_US